Experiences with

Enzalutamide

The enzalutamide monotherapy was almost as effective as enzalutamide plus leuprolide with fewer hot flushes, hypertension, falls and fractures. The reduced fractures show that the monotherapy avoids bone loss. Therefore, Xgeva is probably not required.

-Patrick [1] https://www.urologytimes.com/view/enzalutamide-sustains-survival-benefit-in-mhspc-with-over-5-years-follow-up [2] https://www.urologytimes.com/view/dr-ian-davis-on-5-year-enzalutamide-survival-data-in-mhspc

metastatic castration-resistant prostate cancer (mCRPC) vs enzalutamide and apalutamide.

The median MFS was NR (95% CI, NR-NR) in the enzalutamide monotherapy arm.

We have not formally compared the abiraterone and enzalutamide trial with trials testing enzalutamide. But, given the similar efficacy reported when combining enzalutamide with androgen deprivation therapy, we also conclude that combining abiraterone with enzalutamide would not be more effective.

also suggest enzalutamide may inhibit P-gp, though in vivo studies have yet to corroborate this finding.

Enzalutamide monotherapy could probably be used instead of Lupron after radiation too.

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review. You X, Huang S, Wang X, Yi C, Gong N, Yu J, Xu C, Xiang Z.

My Question is, should I switch the abiraterone for enzalutamide. There is some evidence for switching these drugs if one is no longer working. Apparently the dexamethasone is not good for bone health. Xgeva every 3 months, Xofigo every month for 6 months and possibly add enzalutamide.

Has anyone ordered enzalutamide from India? If so were there any problems, and what pharmacy did you use? There seems to be a plethora of them.

We have identified (R)-9b as a `third generation' of AR-antagonist, which has ability to overcome Enzalutamide and abiraterone-resistant prostate cancer.

More from ASCO 2023 [1]: “We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,

Hi, I have advanced metastatic hormone sensitive prostate cancer and as well as my usual three monthly ADT (Lucrin-Depot) injection, I have been offered either Enzalutamide (Xtandi) or Darolutamide (Nubeqa). My PSA is currently below 0.1 due to the Lucrin-Depot.

I have high volume mrpca and have had triplit therapy with enzalutamide at 160 mg per day. My response has been great with PCA falling from 700 at diagnosis to undetectable at 3 measurements over the last 6 months.

Interestingly, the PSA-PFS for enzalutamide increased from 3.8 months after abiraterone to 10.9 months after BAT, and PFS2 with BAT followed by enzalutamide was significantly longer than with enzalutamide followed by BAT, proving the hypothesis that BAT can re-sensitise CRPC to subsequent antiandrogen

This is a one-off case, but I wanted to share, just to help those of you on Enzalutamide, to be aware that this is possible: https://cardiooncologyjournal.biomedcentral.com/articles/10.1186/s40959-023-00160-7

By combining the PARP inhibitor (Lynparza (olaparib) or Talzenna (talazoparib)) with either abiraterone or enzalutamide, cancer progression was slowed, even in men who were BRCA-.

On Hormonal Trmt Enzalutamide. Has anyone undergo Prostactomy Da Vinci Surgery?

On Hormonal Trmt Enzalutamide. Has anyone undergo Prostactomy Da Vinci Surgery?

On Hormonal Trmt Enzalutamide. Has anyone undergo Prostactomy Da Vinci Surgery?